ArticleJournal of cancer research and clinical oncology2011
An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy.PloS one · 2017Pooled it
- [Research progress on liver transplantation therapy for hepatic metastases in gastroenteropancreatic neuroendocrine tumors].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Association between CD4Oncology letters · 2024Article
- The predictive value of peripheral blood CD4 cells ATP concentration for immune-related adverse events in advanced non-small cell lung cancer patients.BMC immunology · 2024Article
- High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer.Journal of clinical laboratory analysis · 2021Article
- Transcriptome analysis identifies metallothionein as biomarkers to predict recurrence in hepatocellular cacinoma.Molecular genetics & genomic medicine · 2019Article
- Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review.Oncotarget · 2017Review
- Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.World journal of gastroenterology · 2016Article
- Peripheral blood CD4(+) cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant.International journal of clinical practice · 2016Article
- Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.World journal of gastroenterology · 2016Review
- Current status and perspectives of immune-based therapies for hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- Immune monitoring post liver transplant.World journal of transplantation · 2014Review
- Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation.PloS one · 2014Article
- Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis.World journal of gastroenterology · 2013Review
- Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.Hepatology research : the official journal of the Japan Society of Hepatology · 2013Article
- Factors predicting survival after post-transplant hepatocellular carcinoma recurrence.Journal of hepato-biliary-pancreatic sciences · 2013Article
- Proper assessment and prognostication of patients with hepatocellular carcinoma.Clinical liver diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAn immune function assay has been proposed as a new strategy to monitor immunosuppression after organ transplantation. However, there are limited data regarding its role in liver transplant recipients with hepatocellular carcinoma (HCC). In this study, we sought to determine the utility of this functional assay in assessing the risk of infection, rejection, and tumor recurrence in liver transplant recipients.
methodsImmune function was determined by ImmuKnow assay that measures the amount of adenosine triphosphate (ATP) produced by CD4 (+) T cells to monitor the global immune status in 342 whole blood samples from 105 liver transplant recipients. The association between ATP value and post-transplant tumor recurrence was evaluated in 60 HCC patients. The ATP value in predicting tumor recurrence in other independent cohort of 92 recipients with HCC was analyzed prospectively.
resultsThe mean ATP values of liver transplant recipients with infection (145.2 ± 87.0 ng/ml) or acute rejection (418.9 ± 169.5 ng/ml) were different from those with stable state (286.6 ± 143.9 ng/ml, P < 0.05). In recipients with HCC who developed recurrent tumors, the values were significantly lower than those without recurrence (137.8 ± 66.4 vs. 289 ± 133.9 ng/ml, P < 0.01); the optimal threshold value to predict post-transplant tumor recurrence was 175 ng/ml. Comparing with the patients in lower immune group (ATP ≤ 175 ng/ml), patients in the higher immune group (ATP > 175 ng/ml) experienced significantly better disease-free survival (P < 0.01). Multivariate Cox regression analysis showed the ATP value was an independent predictor of HCC recurrence.
conclusionsThe immune function assay has the potential to assess the risk of infection and rejection in liver transplantation and to predict post-transplant tumor recurrence in recipients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.